Skip to main content
. 2015 Oct 26;6(39):42150–42168. doi: 10.18632/oncotarget.6243

Table 1. Characterization of blank NPs and drug encapsulated NPs.

Groups Particle size (nm) Polydispersity Zeta potential (mV)
FA-PEG-PLGA NPs 134.71±6.42 0.165±0.015 −26.12±1.23
CDDP-FA-NPs 149.38±9.04 0.187±0.018 −22.48±0.97
PTX-FA-NPs 161.81±6.97 0.172±0.025 −23.51±1.34
Co-FA-NPs (CDDP: PTX = 2:1) 171.36±8.67 0.133±0.008 −21.50±0.88
Co-FA-NPs (CDDP: PTX = 1:1) 177.23±10.79 0.151±0.013 −22.78±1.16
Co-FA-NPs (CDDP: PTX = 1:2) 185.94±7.43 0.158±0.012 −24.68±1.21
Co-NPs (CDDP: PTX = 1:2) 176.56±4.83 0.161±0.016 −23.07±0.98

Diameter and zeta potential were determined by DLS. Three batches of samples (1 mg/mL) were prepared by directly dissolving NPs in distilled water, then sonication 5 min.